 Canaccord Genuity reiterated their buy rating on shares of Agios Pharmaceuticals NASDAQ:AGIO in a research report released on Friday, AnalystRatings.com reports. They currently have a 72.00 target price on the biopharmaceutical companys stock. AGIO has been the subject of a number of other reports. Citigroup boosted their target price on shares of Agios Pharmaceuticals from ... 